Evidence map›Paper›PMID 32227662›Full record

ArticleChembiochem : a European journal of chemical biology2020

Nitroreductase-Mediated Release of Inhibitors of Lysine-Specific Demethylase 1 (LSD1) from Prodrugs in Transfected Acute Myeloid Leukaemia Cells.

Eva-Maria Herrlinger, Mirjam Hau, Desiree Melanie Redhaber, Gabriele Greve, Dominica Willmann, Simon Steimle, Michael Müller, Michael Lübbert, Christoph Cornelius Miething, Roland Schüle and 1 more

Open access · greenAbstract read
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Eva-Maria HerrlingerDepartment of Chemistry and Pharmacy, University of Freiburg, Institute of Pharmaceutical Sciences, Albertstrasse 25, 79104, Freiburg, Germany.
Mirjam HauDepartment of Chemistry and Pharmacy, University of Freiburg, Institute of Pharmaceutical Sciences, Albertstrasse 25, 79104, Freiburg, Germany.
Desiree Melanie RedhaberDivision of Hematology, Oncology and Stem Cell Transplantation, University of Freiburg Medical Center, Hugstetter Strasse 55, 79106, Freiburg, Germany.
Gabriele GreveDivision of Hematology, Oncology and Stem Cell Transplantation, University of Freiburg Medical Center, Hugstetter Strasse 55, 79106, Freiburg, Germany.
Dominica WillmannDepartment of Urology and Center for Clinical Research, University of Freiburg Medical Center, Breisacher Strasse 66, 79106, Freiburg, Germany.ORCID 0000-0002-4714-690X
Simon SteimleDepartment of Chemistry and Pharmacy, University of Freiburg, Institute of Pharmaceutical Sciences, Albertstrasse 25, 79104, Freiburg, Germany.
Michael MüllerDepartment of Chemistry and Pharmacy, University of Freiburg, Institute of Pharmaceutical Sciences, Albertstrasse 25, 79104, Freiburg, Germany.ORCID 0000-0002-2742-4992
Michael LübbertDivision of Hematology, Oncology and Stem Cell Transplantation, University of Freiburg Medical Center, Hugstetter Strasse 55, 79106, Freiburg, Germany.
Christoph Cornelius MiethingDivision of Hematology, Oncology and Stem Cell Transplantation, University of Freiburg Medical Center, Hugstetter Strasse 55, 79106, Freiburg, Germany.ORCID 0000-0003-4699-3805
Roland SchüleCIBSS - Centre for Integrative Biological Signalling Studies, University of Freiburg, Schänzlestrasse 18, 79104, Freiburg, Germany.ORCID 0000-0001-8147-634X
Manfred JungDepartment of Chemistry and Pharmacy, University of Freiburg, Institute of Pharmaceutical Sciences, Albertstrasse 25, 79104, Freiburg, Germany.ORCID 0000-0002-6361-7716
University of Freiburg · DE

Funding

European Research Council 322844
6 · The paper itself

Abstract

Lysine-specific demethylase 1 (LSD1) has evolved as a promising therapeutic target for cancer treatment, especially in acute myeloid leukaemia (AML). To approach the challenge of site-specific LSD1 inhibition, we developed an enzyme-prodrug system with the bacterial nitroreductase NfsB (NTR) that was expressed in the virally transfected AML cell line THP1-NTR

Indexed as

Drug LiberationCell Line, TumorCell SurvivalDrug DesignEnzyme InhibitorsHistone DemethylasesHumansLeukemia, Myeloid, AcuteNitroreductasesProdrugsTransfectionEnzyme InhibitorsHistone DemethylasesKDM1A protein, humanNitroreductasesProdrugschemistrydrug designinhibitorsluminescence medicinaloxidoreductasesprodrugs

Identifiers

PMID32227662
PMCPMC7497180
OpenAlexW3013037695

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.